The selenium (Se)-containing antioxidant selenoneine (2-selenyl-N α,N α,N α-trimethyl-L-histidine) has recently been discovered to be the predominant form of organic Se in tuna blood. Although dietary intake of fish Se has been suggested to reduce methylmercury (MeHg) toxicity, the molecular mechanism of MeHg detoxification by Se has not yet been determined. Here, we report evidence that selenoneine accelerates the excretion and demethylation of MeHg, mediated by a selenoneine-specific transporter, organic cations/carnitine transporter-1 (OCTN1). Selenoneine was incorporated into human embryonic kidney HEK293 cells transiently overexpressing OCTN1 and zebrafish blood cells by OCTN1. The K m for selenoneine uptake was 13.0 μM in OCTN1-overexpressing HEK293 cells and 9.5 μM in zebrafish blood cells, indicating high affinity of OCTN1 for selenoneine in human and zebrafish cells. When such OCTN1-expressing cells and embryos were exposed to MeHg-cysteine (MeHgCys), MeHg accumulation was decreased and the excretion and demethylation of MeHg were enhanced by selenoneine. In addition, exosomal secretion vesicles were detected in the culture water of embryos that had been microinjected with MeHgCys, suggesting that these may be responsible for MeHg excretion and demethylation. In contrast, OCTN1-deficient embryos accumulated MeHg, and MeHg excretion and demethylation were decreased. Furthermore, Hg accumulation was decreased in OCTN1-overexpressing HEK293 cells, but not in mock vector-transfected cells, indicating that selenoneine and OCTN1 can regulate MeHg detoxification in human cells. Thus, the selenoneine-mediated OCTN1 system regulates secretory lysosomal vesicle formation and MeHg demethylation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742965PMC
http://dx.doi.org/10.1007/s10126-013-9508-1DOI Listing

Publication Analysis

Top Keywords

excretion demethylation
16
octn1 selenoneine
12
hek293 cells
12
mehg
10
cells
9
selenoneine
8
mehg detoxification
8
demethylation mehg
8
zebrafish blood
8
blood cells
8

Similar Publications

Fecal microbiota transplantation as an effective way in treating methylmercury-poisoned rats.

Sci Total Environ

December 2024

CAS-HKU Joint Laboratory of Metallomics on Health and Environment, & CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, & Beijing Metallomics Facility, & National Consortium for Excellence in Metallomics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China; University of Chinese Academy of Sciences, Beijing 100049, China. Electronic address:

Article Synopsis
  • * The study investigated the impact of fecal microbiota transplantation (FMT) on rats poisoned with MeHg over a 14-day treatment period, analyzing neurological behaviors, weight changes, and levels of MeHg and dopamine.
  • * Results showed that FMT significantly improved weight gain, reduced neurological problems, increased mercury excretion, restored gut microbiota, and boosted beneficial metabolites, suggesting potential applications for treating neurological conditions like Parkinson's Disease.
View Article and Find Full Text PDF

Identification of Beauvericin metabolites using rat and human liver microsomes and in vivo urinary excretion study in rats for biomonitoring application.

Toxicol In Vitro

March 2025

Toxicokinetics Laboratory, ASSIST and REACT Division, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India. Electronic address:

Beauvericin (BEA), an emerging mycotoxin, belongs to a class characterized by a cyclic depsipeptide ring structure, commonly produced by fungal species like Fusarium sp. and Beauveria bassiana. BEA is known for contaminating cereals and grains (wheat, maize).

View Article and Find Full Text PDF

Preclinical metabolism and disposition of [C]GFH009, a novel selective CDK9 inhibitor.

Xenobiotica

October 2024

GenFleet Therapeutics (Shanghai) Inc., Shanghai, P. R. China.

GFH009 is a potent and highly selective cyclin-dependent kinase 9 (CDK9) inhibitor currently under phase II clinical trials. In this study, we investigated the metabolism and disposition of GFH009 in Sprague-Dawley (SD) rats, as well as metabolism of CD-1 mouse, SD rat, beagle dog, cynomolgus monkey, and human.A radiolabelled study indicated that [C]GFH009 was quickly and widely distributed throughout the body, but presented low levels in brain, testis, and epididymis after a single intravenous dose of 6 mg (100 µCi)/kg to SD rats.

View Article and Find Full Text PDF

Metabolic and Pharmacokinetic Profiling Studies of N, N-Dimethylaniline-Heliamine in Rats by UHPLC-Q-Orbitrap MS/MS.

Molecules

September 2024

State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization, CAS Key Laboratory of Chemistry of Plant Resources in Arid Regions, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi 830011, China.

Article Synopsis
  • Cardiovascular disease is the leading cause of death globally, and DH, a synthetic compound, shows promise as an antiarrhythmic agent despite limited research on its metabolic behavior in rats.
  • This study identifies 16 metabolites of DH and establishes a reliable method for measuring DH levels in rat plasma, focusing on different metabolic processes such as demethylation and glucuronidation.
  • The findings indicate that DH is well-absorbed with significant tissue distribution, having low toxicity and various excretion pathways.
View Article and Find Full Text PDF

Absorption, Distribution, Metabolism, and Excretion of Icenticaftor (QBW251) in Healthy Male Volunteers at Steady State and In Vitro Phenotyping of Major Metabolites.

Drug Metab Dispos

November 2024

Novartis Pharma AG, Basel, Switzerland (U.G., F.H., F.E., L.A.L., A.M., L.B.) and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey (M.H.).

Icenticaftor (QBW251) is a potentiator of the cystic fibrosis transmembrane conductance regulator protein and is currently in clinical development for the treatment of chronic obstructive pulmonary disease and chronic bronchitis. An absorption, distribution, metabolism, and excretion study was performed at steady state to determine the pharmacokinetics, mass balance, and metabolite profiles of icenticaftor in humans. In this open-label study, six healthy men were treated with unlabeled oral icenticaftor (400 mg b.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!